Given better survival in pediatric patients with acute lymphoblastic leukemia (ALL) compared with adolescents and young adults (AYAs), oncologists are exploring the toxicity and overall tolerability of using pediatric-inspired regimens for AYA patients.
Children and young adults with acute lymphoblastic leukemia (ALL) who live more than 50 miles away from a treatment center face inferior survival outcomes, according to a recent study. Pediatric hematologist-oncologists Rabi Hanna, MD and Seth Rotz, MD, discuss the implications of their findings.
A pediatric-inspired post-remission chemotherapy regimen is more effective than myeloablative allogeneic hematopoietic cell transplantation in treating adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission, new research shows.
The promising preliminary survival and remission outcomes that inotuzumab ozogamicin produced in relapsed or refractory acute lymphoblastic leukemia patients in the antibody-drug conjugate’s Phase 3 trial have been sustained in a long-term follow-up study.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Evidence regarding the genetic pathways involved in Scwachman-Diamond syndrome and severe congenital neutropenia is emerging. Clinician researcher Seth Corey, MD, MPH, explains his work to identify patients at highest risk and intervene before acute myeloid leukemia develops.
An analysis of outcomes for infant allogeneic hematopoietic transplant recipients finds mixed results, with some signs of progress but no recent survival gains in patients with malignant diagnoses.
Patients with hematologic first cancers (myeloid lineage or plasma cell dyscrasias) had the greatest risk of developing ALL as a second cancer.
The FDA has approved the immunocellular therapy for use in children and young adults with relapsed/refractory B-cell precursor ALL.
Several promising antibody-based treatment strategies are in development for acute lymphoblastic leukemia and acute myeloid leukemia. These could change the decade-old treatment paradigm.